Last reviewed · How we verify
C-Tb
C-Tb is a tuberculosis vaccine candidate that stimulates immune responses against Mycobacterium tuberculosis antigens to prevent or treat tuberculosis infection.
C-Tb is a tuberculosis vaccine candidate that stimulates immune responses against Mycobacterium tuberculosis antigens to prevent or treat tuberculosis infection. Used for Tuberculosis (TB) as adjunctive therapy with standard anti-TB chemotherapy.
At a glance
| Generic name | C-Tb |
|---|---|
| Also known as | rdESAT-6 + rCFP-10 |
| Sponsor | Statens Serum Institut |
| Drug class | Subunit vaccine |
| Target | Mycobacterium tuberculosis antigens (ESAT-6, CFP-10) |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
C-Tb is a subunit vaccine containing recombinant TB antigens (likely including ESAT-6 and CFP-10) designed to boost cellular immunity against tuberculosis. It is intended to be used as a therapeutic vaccine in combination with standard TB chemotherapy to enhance immune clearance of the pathogen and potentially improve treatment outcomes.
Approved indications
- Tuberculosis (TB) as adjunctive therapy with standard anti-TB chemotherapy
Common side effects
- Injection site reactions (pain, erythema, induration)
- Fever
- Fatigue
- Headache
Key clinical trials
- ID93/GLA-SE Vaccination + BCG Challenge (NA)
- Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition (TB-Speed SAM) (NA)
- A PAN-USR TB Multi-Center Trial (PHASE3)
- Start Taking Action For TB Diagnosis
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB (PHASE2)
- Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis
- ESAT6/CFP10 Skin Testing for TB Infection in Rheumatologic Patients
- Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C-Tb CI brief — competitive landscape report
- C-Tb updates RSS · CI watch RSS
- Statens Serum Institut portfolio CI